基于FDA不良事件报告系统 (FAERS) 数据库的果丁尼布的现实世界药监测研究
Yajing Xu1, Dongchen Wang2, Yuyan Xu3
1Department of Radiation Oncology, Wenzhou Central Hospital, Wenzhou, China.
Cancer medicine
|November 7, 2025
概括
这项研究在市场后监测中发现了与结直肠癌药物fruquintinib相关的新不良事件 (AE). 早期检测这些果丁尼布副作用可以改善患者的安全性和治疗策略.
科学领域:
- 药监和药物安全 药监和药物安全
- 瘤学 治疗学 治疗学
- 监管科学 监管科学
背景情况:
- 弗鲁昆丁尼布是一种经批准的小分子抑制剂,向转移性结直肠癌的血管内皮生长因子受体.
- 越来越多的临床使用需要对不良事件 (AE) 进行全面的药物监测.
研究的目的:
- 为了对与fruquintinib相关的不良事件进行药监测评估.
- 识别新的AE并描述时间风险模式.
主要方法:
- 从2023年第四季度到2025年第一季度对FDA不良事件报告系统 (FAERS) 数据库的分析.
- 使用了四种不成比例分析方法 (ROR,PRR,MGPS,BCPNN) 和韦布尔分布建模.
- 使用医学监管活动词典 (MedDRA) 系统器官类 (SOC) 和首选术语 (PT) 进行特征性的AE.
主要成果:
- 分析了1632份报告;78个PT满足了所有四个算法的标准.
- 确定了以前未被识别的AE:大肠道阻塞,脱水,外围神经病变,脏有限的血栓性微血管病变和后部可逆脑病变综合征.
- 平均AE发病时间为18天,其中66.16%发生在第一个月内.
结论:
- 研究结果与已知的fruquintinib的临床观察结果一致.
- 检测到与fruquintinib相关的新型副作用,增强了临床监测和风险评估.
相关概念视频
Pharmacovigilance
1.6K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.6K
Drug Regulation
2.7K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
2.7K
Clinical Trials: Overview
4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
Therapeutic Drug Monitoring: Affecting Factors
189
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
189
FDA Approved Drugs: Changes to Approved Drugs
236
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
236
Therapeutic Drug Monitoring: Overview and Classification
282
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
282


